EyEnovIA Files 8-K: Material Agreement, Equity Sales
Ticker: HYPD · Form: 8-K · Filed: Jan 16, 2025 · CIK: 1682639
| Field | Detail |
|---|---|
| Company | Eyenovia, INC. (HYPD) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $0.69, $0.0659, $1.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
EYENOVIA signed a big deal & sold stock, filing 8-K on Jan 16.
AI Summary
On January 16, 2025, EyEnovIA, Inc. entered into a Material Definitive Agreement. The company also reported on Unregistered Sales of Equity Securities and filed Financial Statements and Exhibits. Specific details regarding the agreement and sales were not provided in this excerpt.
Why It Matters
This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing mentions a Material Definitive Agreement and unregistered sales of equity, which can introduce financial and operational risks if not managed properly.
Key Players & Entities
- EYENOVIA, INC. (company) — Registrant
- January 16, 2025 (date) — Date of earliest event reported
- 295 Madison Avenue, Suite 2400, New York, NY 10017 (address) — Principal Executive Offices
FAQ
What is the nature of the Material Definitive Agreement entered into by EyEnovIA, Inc. on January 16, 2025?
The provided excerpt does not specify the details of the Material Definitive Agreement.
What type of equity securities were sold in the unregistered sales reported by EyEnovIA, Inc.?
The excerpt mentions unregistered sales of equity securities but does not provide specific details about the type of securities.
What are the key financial highlights or exhibits filed with this 8-K report?
The excerpt indicates that Financial Statements and Exhibits were filed, but their specific content is not detailed here.
What is EyEnovIA, Inc.'s IRS Employer Identification Number?
EyEnovIA, Inc.'s IRS Employer Identification Number is 47-1178401.
What is the SEC file number for EyEnovIA, Inc.?
EyEnovIA, Inc.'s SEC file number is 001-38365.
Filing Stats: 1,292 words · 5 min read · ~4 pages · Grade level 12.7 · Accepted 2025-01-16 11:56:32
Key Financial Figures
- $0.0001 — h registered) Common stock, par value $0.0001 per share EYEN The Nasdaq Stock Mar
- $0.69 — low, were all exercisable at a price of $0.69 per share of common stock. On January
- $0.0659 — cisability date at an exercise price of $0.0659 per share. Such approval will be sought
- $1.0 million — gregate gross proceeds of approximately $1.0 million from the exercise of the Existing Warra
Filing Documents
- tm253514d1_8k.htm (8-K) — 32KB
- tm253514d1_ex4-1.htm (EX-4.1) — 100KB
- tm253514d1_ex4-2.htm (EX-4.2) — 97KB
- tm253514d1_ex10-1.htm (EX-10.1) — 59KB
- 0001104659-25-004007.txt ( ) — 531KB
- eyen-20250116.xsd (EX-101.SCH) — 3KB
- eyen-20250116_lab.xml (EX-101.LAB) — 33KB
- eyen-20250116_pre.xml (EX-101.PRE) — 22KB
- tm253514d1_8k_htm.xml (XML) — 4KB
01 Entry into a Material Definitive
Item 1.01 Entry into a Material Definitive Agreement. Warrant Repricing On March 3, 2022, August 24, 2023 and July 1, 2024, Eyenovia, Inc., a Delaware corporation (the "Company"), entered into certain securities purchase agreements with an institutional investor (the "Investor"), pursuant to which the Company issued and sold warrants (the "Existing Warrants") to purchase up to an aggregate of 15,769,445 shares of the Company's common stock, par value $0.0001 per share (the "common stock"), to the Investor. The Existing Warrants will expire between 2027 and 2029 and, prior to the repricing described below, were all exercisable at a price of $0.69 per share of common stock. On January 16, 2025, the Company entered into a warrant inducement offer letter with the Investor (the "Inducement Letter") pursuant to which the Company agreed to reduce the exercise price of the Existing Warrants, and the Investor exercised all of the repriced Existing Warrants for an aggregate of 15,769,445 shares of common stock. In consideration for exercising those Existing Warrants, pursuant to the terms of the Inducement Letter, the Company agreed to issue to the Investor a new Series A Common Stock Purchase Warrant (the "Series A Warrant") and a new Series B Common Stock Purchase Warrant (the "Series B Warrant" and, together with the Series A Warrant, the "New Warrants"), to purchase up to a number of shares of common stock equal to 200% of the number of shares of common stock issued pursuant to the exercise of the Existing Warrants. The New Warrants, which are expected to be issued on January 17, 2025, are expected to be exercisable upon receipt of approval of the Company's stockholders in accordance with the applicable rules and regulations of The Nasdaq Capital Market, and may be exercised for five years from the initial exercisability date at an exercise price of $0.0659 per share. Such approval will be sought at a meeting of shareholders to be held within 120 days of the date on
01. Exhibits
Item 9.01. Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Series A Common Stock Purchase Warrant 4.2 Form of Series B Common Stock Purchase Warrant 10.1 Form of Warrant Inducement Offer Letter 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYENOVIA, INC. Date: January 16, 2025 /s/ Michael Rowe Michael Rowe Chief Executive Officer